Literature DB >> 32951136

An Opioid-Sparing Protocol Improves Recovery Time and Reduces Opioid Use After Laparoscopic Sleeve Gastrectomy.

Benjamin Pardue1, Austin Thomas1, Jake Buckley2, William J Suggs3,4.   

Abstract

PURPOSE: The current literature is sparse on post discharge pain management for bariatric surgical patients. This study aimed to determine if an opioid-sparing protocol could decrease opioid use during the postoperative period (hospital to home).
MATERIALS AND METHODS: In this retrospective cohort study, we implemented an opioid-sparing protocol in January 2018, for patients undergoing laparoscopic sleeve gastrectomy (LSG) at our institution. We compared recovery time, pain scores (in hospital and at home), and perioperative opioid use between the historic control group (February 2017 to December 2017) and the opioid-sparing group (January 2018 to December 2018). A p value of < .05 was considered statistically significant.
RESULTS: The study included 400 patients (200 in each group), and 165 participated in the phone survey. Baseline characteristics were similar, except the control group had a higher body mass index and body weight. The average recovery time was significantly shorter in the opioid-sparing group (18.9 versus 35.3 days, P = .043). There was no significant difference in mean postoperative pain scores in the hospital or at home. The opioid-sparing group required significantly fewer opioids postoperatively (10.4 versus 16.1 morphine milligram equivalents, P < .001). Only 1 out of the 200 patients in the opioid-sparing arm requested an opioid prescription after discharge.
CONCLUSION: Implementation of an opioid-sparing protocol improved recovery time and reduced postoperative opioid use in the hospital and after discharge without changing perceived pain in patients undergoing LSG.

Entities:  

Keywords:  Laparoscopic sleeve gastrectomy; Multimodal analgesia; Opioid consumption; Opioid-sparing; Pain control; Recovery time

Mesh:

Substances:

Year:  2020        PMID: 32951136     DOI: 10.1007/s11695-020-04980-9

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  23 in total

1.  Wide Variation and Excessive Dosage of Opioid Prescriptions for Common General Surgical Procedures.

Authors:  Maureen V Hill; Michelle L McMahon; Ryland S Stucke; Richard J Barth
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

Review 2.  Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations.

Authors:  A Thorell; A D MacCormick; S Awad; N Reynolds; D Roulin; N Demartines; M Vignaud; A Alvarez; P M Singh; D N Lobo
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

Review 3.  Meta-Analysis of Enhanced Recovery Protocols in Bariatric Surgery.

Authors:  Ola S Ahmed; Ailín C Rogers; Jarlath C Bolger; Achille Mastrosimone; William B Robb
Journal:  J Gastrointest Surg       Date:  2018-02-27       Impact factor: 3.452

4.  Multimodal Postoperative Pain Control Is Effective and Reduces Opioid Use After Laparoscopic Roux-en-Y Gastric Bypass.

Authors:  Ryan D Horsley; Ellen D Vogels; Daaron A P McField; David M Parker; Charles Medico; James Dove; Marcus Fluck; Jon D Gabrielsen; Michael R Gionfriddo; Anthony T Petrick
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

5.  Employing Enhanced Recovery Goals in Bariatric Surgery (ENERGY): a national quality improvement project using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program.

Authors:  Stacy A Brethauer; Arielle Grieco; Teresa Fraker; Kimberly Evans-Labok; April Smith; Matthew D McEvoy; Alan A Saber; John M Morton; Anthony Petrick
Journal:  Surg Obes Relat Dis       Date:  2019-09-23       Impact factor: 4.734

6.  Postoperative Opioid Prescribing Practices and Evidence-Based Guidelines in Bariatric Surgery.

Authors:  Danielle T Friedman; Saber Ghiassi; Matthew O Hubbard; Andrew J Duffy
Journal:  Obes Surg       Date:  2019-07       Impact factor: 4.129

7.  Use of prescribed opioids before and after bariatric surgery: prospective evidence from a U.S. multicenter cohort study.

Authors:  Wendy C King; Jia-Yuh Chen; Steven H Belle; Anita P Courcoulas; Gregory F Dakin; David R Flum; Marcelo W Hinojosa; Melissa A Kalarchian; James E Mitchell; Walter J Pories; Konstantinos Spaniolas; Bruce M Wolfe; Susan Z Yanovski; Scott G Engel; Kristine J Steffen
Journal:  Surg Obes Relat Dis       Date:  2017-04-07       Impact factor: 4.734

8.  Effect of new persistent opioid use on physiologic and psychologic outcomes following bariatric surgery.

Authors:  Margaret E Smith; Jay S Lee; Aaron Bonham; Oliver A Varban; Jonathan F Finks; Arthur M Carlin; Amir A Ghaferi
Journal:  Surg Endosc       Date:  2018-10-23       Impact factor: 4.584

9.  A Multimodal Analgesic Protocol Reduces Opioid-Related Adverse Events and Improves Patient Outcomes in Laparoscopic Sleeve Gastrectomy.

Authors:  Jun Jie Ng; Wei Qi Leong; Chuen Seng Tan; Keah How Poon; Davide Lomanto; Jimmy B Y So; Asim Shabbir
Journal:  Obes Surg       Date:  2017-12       Impact factor: 4.129

Review 10.  Prescription Opioid Analgesics Commonly Unused After Surgery: A Systematic Review.

Authors:  Mark C Bicket; Jane J Long; Peter J Pronovost; G Caleb Alexander; Christopher L Wu
Journal:  JAMA Surg       Date:  2017-11-01       Impact factor: 14.766

View more
  2 in total

1.  Implementation of a standardized multimodal pain regimen significantly reduces postoperative inpatient opioid utilization in patients undergoing bariatric surgery.

Authors:  Wen Hui Tan; Jordanne Ford; Tammy Kindel; Rana M Higgins; Kathleen Lak; Jon C Gould
Journal:  Surg Endosc       Date:  2022-08-04       Impact factor: 3.453

Review 2.  Opioid prescribing practices following bariatric surgery: a systematic review and pooled proportion meta-analysis.

Authors:  Andrea Lin; Kevin Verhoeff; Valentin Mocanu; Kieran Purich; Khadija Nasser; Janice Y Kung; Daniel W Birch; Shahzeer Karmali; Noah J Switzer
Journal:  Surg Endosc       Date:  2022-08-04       Impact factor: 3.453

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.